Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

Sarah B. Goldberg(Yale Cancer Center), Scott Gettinger(Yale Cancer Center), Amit Mahajan(Yale Cancer Center), Anne C. Chiang(Yale University), Roy S. Herbst(Yale Cancer Center), Mario Sznol(Yale University), Apostolos John Tsiouris(Cornell University), Justine V. Cohen(Yale Cancer Center), Alexander O. Vortmeyer(Yale Cancer Center), Lucia B. Jilaveanu(Yale University), James B. Yu(Yale Cancer Center), Upendra P. Hegde(UConn Health), Stephanie Speaker(Yale University), Matthew Madura(Yale Cancer Center), Amanda Ralabate(Yale University), Angel L. Rivera(Yale University), Elin Rowen(Yale Cancer Center), Heather Gerrish(Yale University), Xiaopan Yao(Yale University), Veronica Chiang(Yale Cancer Center), Harriet M. Kluger(Yale Cancer Center)
The Lancet Oncology
June 4, 2016
10.1016/s1470-2045(16)30053-5
Cited by 994Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis